GSK Consumer Unit Gets 483 for Internal Audit Shortfalls

GlaxoSmithKline Consumer Healthcare has received an FDA Form 483 for not conducting internal audits at its Saint Louis, Mo., plant as often as required by company protocol. During an Oct. 19 to Nov. 2, 2011, inspection, the FDA found audit schedules were not followed for stability, packaging, tableting and quality of incoming supplies, the form states.
Drug GMP Report